+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-04-27Number of Pages: 104

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2014 - 2020

 
Therapeutic peptides are defined as short amino acid chains that have potential in managing disease symptoms, and in some cases cure them. The industry defines peptides as molecules shorter than 100 amino acids; while longer amino acid chains can be monoclonal antibodies and proteins. Insulin was the first peptide to be isolated and administered therapeutically, and is still the most commonly prescribed peptide, having been used for over half a century. Peptides have been explored for the treatment of various conditions such as cancer, cardiovascular disorders, respiratory disorders, blood disorders, central nervous system disorders and various others.  
 
The peptide therapeutics market has developed at a significant pace in the recent past, leading to unparalleled growth in the number of regulatory approvals received in 2012. Thus, the increase in number of approved peptide-based drug products and expanding range of medical indications projects the increasing maturity of peptides as a class of pharmaceutical actives. Therapeutic peptides are approved for various application areas such as cancer, cardiovascular, central nervous system, gastrointestinal, infection, metabolic, pain, and respiratory. Cancer was estimated to be the largest application segment of the peptide therapeutics market in 2013; while the respiratory segment is expected to grow at the highest CAGR, due to the recent approval of Surfaxin (lucinactant). Major drugs driving growth of the overall peptide therapeutics market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. However, difficulty in synthesis of complex peptides has restricted growth of the generic peptide drugs market. 
 
Patent expiry has been the prime factor impeding market growth; while at the same time has also allowed deeper market penetration in low and middle income countries. The market is also restrained due to unavailability of convenient routes of drug administration, and lower drug stability at room temperature. Scientists, however, are trying to overcome these drawbacks through consistent research and development. With an escalating number of peptide therapeutic drug approvals and consistent launch of generics, the demand for peptide APIs is expected to rise in the near future. Hence, API manufacturers are trying to optimize economies of scale to reduce costs and also meet the rising peptide API demand. Thus, the supply side of the peptide therapeutics value chain would decide the fate of the global market.   
 
The global peptide therapeutics market is largely concentrated in the western countries of North America and Europe, which account for more than 60% of the market share. Although these regions are currently the largest market segments, the compounded annual growth rate of the market in these regions is expected to be slower as compared to Asia Pacific. India, China and Japan are major countries driving the peptide therapeutics market in the Asia Pacific region. Japan is the second-largest individual pharmaceutical market, while India and China have large patient population due to high disease prevalence. Rapidly developing economy and increasing awareness about various disease treatments are other factors driving the market. India and China have emerged as major peptide API suppliers globally.    
 
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group.  Peptisyntha Inc and Lonza Inc.   
 
 

 
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
1.5 Assumptions and Stipulations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
 
Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Introduction
3.2 Emerging Trends in Peptide Therapeutics Market
      3.2.1 Trends in Peptide Manufacturing Technology
      3.2.2 Trends in Peptide API Supply
3.3 Market Dynamics
      3.3.1 Drivers
              3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
              3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
              3.3.1.3 Technological advancements have reduced total production cost of peptides
      3.3.2 Restraints
              3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
              3.3.2.2 Lack of regulatory standards
      3.3.3 Opportunities
              3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
              3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4 Regulatory Scenario
3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyer
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
      3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
3.7 Market Attractiveness Analysis
      3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
3.8 Market Share Analysis
 
Chapter 4 Global Peptide Therapeutics Market, by Applications
4.1 Introduction
      4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
4.2 Cancer
      4.2.1 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.2.2 Zoladex (goserelin)
      4.2.3 Velcade (bortezomib)
      4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
      4.2.5 Others
4.3 Cardiovascular
      4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.3.2 Angiomax (bivalirudin)
      4.3.3 Integrilin (eptifibatide)
4.4 Central Nervous System
      4.4.1 Global Central Nervous System Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.4.2 Copaxone (glatiramer)
4.5 Metabolic Disorders
      4.5.1 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.5.2 Victoza (liraglutide)
      4.5.3 Byetta (exenatide)
      4.5.4 Others
4.6 Infection
      4.6.1 Global Infection Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.6.2 Incivek (telaprevir)
      4.6.3 Victrelis (boceprevir)
4.7 Hematological Disorders
      4.7.1 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.7.2 Firazyr (icatibant)
      4.7.3 Kalbitor (ecallantide)
4.8 Gastrointestinal Disorders
      4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
      4.8.2 Gattex (teduglutide)
      4.8.3 Linzess (linaclotide)
4.9 Respiratory Disorders
      4.9.1 Global Respiratory Disorders Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
4.10 Acromegaly
      4.10.1 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.11 Other Applications
      4.11.1 Global Other Applications Peptide Therapeutics market  Revenue, 2012 - 2020 (USD Million)
 
Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
      5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
5.2 Parenteral Route of Administration
      5.2.1 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
5.3 Oral Route of Administration
      5.3.1 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)
 
Chapter 6 Global Peptide Therapeutics Market, by Marketing Status
6.1 Introduction
      6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
6.2 Branded Peptide Therapeutics
      6.2.1 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
6.3 Generic Peptide Therapeutics
      6.3.1 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
 
Chapter 7 Global Peptide Therapeutics Pipeline Overview
7.1 Introduction
      7.1.1 Global Peptide Therapeutics Pipeline Overview
 
Chapter 8 Global Peptide Therapeutics Market, by Geography
8.1 Introduction
      8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
8.2 North America
      8.2.1 North America Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.3 Europe
      8.3.1 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.4 Asia Pacific
      8.4.1 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.5 Rest of the World
      8.5.1 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
 
Chapter 9 Recommendations
9.1 Rigorous research and development (R&D) would yield new products
9.2 Facility expansion in emerging economies
9.3 Rapid inorganic growth through acquisitions
 
Chapter 10 Company Profiles
10.1 Amgen, Inc.
      10.1.1 Company Overview
      10.1.2 Financial Overview
      10.1.3 Product Portfolio
      10.1.4 Business Strategies
      10.1.5 Recent Developments
10.2 AstraZeneca plc
      10.2.1 Company Overview
      10.2.2 Financial Overview
      10.2.3 Product Portfolio
      10.2.4 Business Strategies
      10.2.5 Recent Developments
10.3 Bachem Holding AG
      10.3.1 Company Overview
      10.3.2 Financial Overview
      10.3.3 Product Portfolio
      10.3.4 Business Strategies
      10.3.5 Recent Developments
10.4 CordenPharma International GmbH
      10.4.1 Company Overview
      10.4.2 Financial Overview
      10.4.3 Product Portfolio
      10.4.4 Business Strategies
      10.4.5 Recent Developments
10.5 Eli Lilly and Company
      10.5.1 Company Overview
      10.5.2 Financial Overview
      10.5.3 Product Portfolio
      10.5.4 Business Strategies
      10.5.5 Recent Developments
10.6 Ipsen S.A.
      10.6.1 Company Overview
      10.6.2 Financial Overview
      10.6.3 Product Portfolio
      10.6.4 Business Strategies
      10.6.5 Recent Developments
10.7 Lonza Group Ltd.
      10.7.1 Company Overview
      10.7.2 Financial Overview
      10.7.3 Product Portfolio
      10.7.4 Business Strategies
      10.7.5 Recent Developments
10.8 Merck & Co., Inc.
      10.8.1 Company Overview
      10.8.2 Financial Overview
      10.8.3 Product Portfolio
      10.8.4 Business Strategies
      10.8.5 Recent Developments
10.9 Novartis AG
      10.9.1 Company Overview
      10.9.2 Financial Overview
      10.9.3 Product Portfolio
      10.9.4 Business Strategies
      10.9.5 Recent Developments
10.10 Novo Nordisk A/S
      10.10.1 Company Overview
      10.10.2 Financial Overview
      10.10.3 Product Portfolio
      10.10.4 Business Strategies
      10.10.5 Recent Developments
10.11 PolyPeptide Group
      10.11.1 Company Overview
      10.11.2 Financial Overview
      10.11.3 Product Portfolio
      10.11.4 Business Strategies
      10.11.5 Recent Developments
10.12 Roche Holdings AG
      10.12.1 Company Overview
      10.12.2 Financial Overview
      10.12.3 Product Portfolio
      10.12.4 Business Strategies
      10.12.5 Recent Developments
10.13 Sanofi
      10.13.1 Company Overview
      10.13.2 Financial Overview
      10.13.3 Product Portfolio
      10.13.4 Business Strategies
      10.13.5 Recent Developments
10.14 Takeda Pharmaceutical Company Limited
      10.14.1 Company Overview
      10.14.2 Financial Overview
      10.14.3 Product Portfolio
      10.14.4 Business Strategies
      10.14.5 Recent Developments
10.15 Teva Pharmaceutical Industries Ltd.
      10.15.1 Company Overview
      10.15.2 Financial Overview
      10.15.3 Product Portfolio
      10.15.4 Business Strategies
      10.15.5 Recent Developments

List of Figures
 
FIG. 1 Peptide Therapeutics Market Segmentation
FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
FIG. 4
FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
FIG. 7 Global Central Nervous System  Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 10 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
FIG. 11 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020  (USD Million)
FIG. 12 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 13 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 14 North America Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 15 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 16 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 17 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 18 Amgen, Inc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Bachem Holding AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Ipsen S.A.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 25 Novartis AG Annual Revenue: 2011 – 2013 (USD Million)
FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 – 2013 (USD Million)
FIG. 27 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 28 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)

List of Tables
 
TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market
TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
TABLE 4 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 7 Global Infection Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 8 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 10 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
TABLE 13 Global Peptide Therapeutics Market Pipeline Overview
TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

Global Peptide Therapeutics Market: Overview

The global market for peptide therapeutics has witnessed development at a significant pace in the past few years, observing a vast rise in the number of peptide drugs being approved and marketed in the global market. The constantly rising number of approvals of peptide-based medicines and the rising array of medical indications finding peptide drugs suitable for effective treatment have cemented the position of peptide therapeutics as one of the most promising fields of the pharmaceutical industry. 

This report on the global peptide therapeutics market is a detailed analysis of the market, its key segments, and various factors influencing the overall development of the market as observed in the present scenario. As such, the report provides an analytical overview of factors such as growth drivers, challenges, key trends of the present and recent times, regulatory landscape of key regional markets, growth opportunities, and competitive scenario in the global peptide therapeutics market.

Global Peptide Therapeutics Market: Segmentation

The report segments the global peptide therapeutics market on the basis of criteria such as application, marketing status of key peptide drugs in the global market, route of administration, and geography.

On the basis of application, the global peptide therapeutics market has been further segmented into cancer, metabolic disorders, central nervous system disorders, cardiovascular disorders, hematological disorders, infection, acromegaly, respiratory disorders, and gastrointestinal disorders. Of these, cancer is presently the class of disease that rakes in the massive share in the revenue of the global peptide therapeutics market. In the near future, however, the segment of respiratory disorders is expected to emerge as the segment with the most promising growth opportunities.

On the basis of marketing status, the report further segments the market into the key branded peptide drugs approved by major regulatory authorities and available for sale in the global market. This segment includes an analysis of leading peptide-based drugs such as Zoladex, Angiomax, Copaxone, Velcade, Forteo, Victoza, and Sandostatin. These drugs are classified on the basis of their status as branded drugs and generic drugs. This section also presents a thorough analysis of the impact of generic peptide drugs on the overall development of the global peptide therapeutics market in the next few years.

On the basis of route of administration, the report segments the market into parenteral and oral. This segment provides the reader a thorough account of the key trends observed in the market related to course of administration of peptide-based drugs. One of the key trends in this area highlighted in the report includes the rising demand for drugs that are convenient to administer.

Global Peptide Therapeutics Market: Geographical and Competitive Dynamics

The report presents a detailed overview of the peptide therapeutics market across key regional markets including Asia Pacific, North America, Europe, and Middle East and Africa. Share and contribution of these regional markets on the revenue of the global market. Aspects such as the presence of key manufacturers, research bodies, growth opportunities, and regulatory aspects governing the peptide therapeutics market and its development in these regions are also analyzed. With the vast rise in prevalence of a large number of chronic diseases and the large population base, Asia Pacific has been highlighted as one of the most promising regions for the peptide therapeutics market.

The company profile section of the report includes a detailed overview of some of the leading players operating in the global peptide therapeutics market. As such, detailed profiles of companies such as CordenPharma International GmbH, Amgen, Inc., Bachem Holding AG, AstraZeneca plc, PolyPeptide Group, Eli Lilly & Co., Merck & Co., Lonza, Inc., Teva Pharmaceutical Industries Limited, Ipsen S.A., Novo Nordisk A/S, Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi, and Roche Holdings AG are included.

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top